Sarcoidosis complicating treatment with natalizumab for Crohn's disease

C A Parisinos, C W Lees, William Wallace, J Satsangi

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients.
Original languageEnglish
Pages (from-to)1109-10
Number of pages2
Issue number12
Publication statusPublished - 2011


Dive into the research topics of 'Sarcoidosis complicating treatment with natalizumab for Crohn's disease'. Together they form a unique fingerprint.

Cite this